Integra LifeSciences Holdings (IART)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Integra LifeSciences Holdings (IART) Stock Forecast
Analysts expect Integra LifeSciences Holdings (IART) to earn $2.34 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.64B. Of 12 analysts, 3 rate the stock Buy or Strong Buy, 7 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 25% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 8.3% |
| Buy | 2 | 16.7% |
| Hold | 7 | 58.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 2 | 16.7% |
- Consensus
- Hold
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 1.3% and revenue estimates rise 1.8%.
- Fiscal year ending Dec 31, 2026
- $2.34
- EPS consensus, revenue $1.64B
- Fiscal year ending Dec 31, 2027
- $2.37
- EPS consensus, revenue $1.67B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.34 | $2.31 to $2.35 | 12 | $1.64B | $1.64B to $1.65B | 11 |
| Dec 31, 2027 | $2.37 | $2.30 to $2.45 | 12 | $1.67B | $1.65B to $1.70B | 11 |
Quarterly Estimates
The EPS consensus falls from $0.68 for the quarter ending Dec 31, 2026 to $0.49 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.68 | $0.61 to $0.88 | 13 | $430.84M | $411.70M to $445.20M | 13 |
| Mar 31, 2027 | $0.49 | $0.41 to $0.60 | 8 | $388.16M | $383.71M to $395.12M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 16 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 5 |
| Fiscal year ending Dec 31, 2027 | 0 | 11 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 4.9% from $2.46.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.34 | $2.33 | $2.41 | $2.46 | $2.46 | -4.9% |
| Fiscal year ending Dec 31, 2027 | $2.37 | $2.39 | $2.60 | $2.61 | $2.61 | -9.0% |
| Quarter ending Mar 31, 2027 | $0.49 | $0.49 | $0.54 | $0.54 | $0.54 | -7.8% |
Frequently Asked Questions About IART
What is the IART stock forecast?
Consensus analyst estimates put Integra LifeSciences Holdings's EPS at $2.34 for the fiscal year ending Dec 31, 2026, on revenue of $1.64B. The consensus rating from 12 analysts is Hold.
How do analysts rate IART stock?
Of 12 analysts covering Integra LifeSciences Holdings, 1 rates it Strong Buy, 2 Buy, 7 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from IART next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.34, with estimates from $2.31 to $2.35 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.37, with estimates from $2.30 to $2.45 from 12 analysts.
What revenue do analysts expect from Integra LifeSciences Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.64B, with estimates from $1.64B to $1.65B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.67B, with estimates from $1.65B to $1.70B.
How many analysts cover IART?
12 analysts rate Integra LifeSciences Holdings stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IART pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors